From the journal Circulation on August 19, 2019:
The use of n-3 FA (4 g/d) for improving atherosclerotic cardiovascular disease risk in patients with hypertriglyceridemia is supported by a 25% reduction in major adverse cardiovascular events in REDUCE-IT (Reduction of Cardiovascular Events With EPA Intervention Trial), a randomized placebo-controlled trial of EPA-only in high-risk patients treated with a statin.
The results of a trial of 4 g/d prescription EPA+DHA in hypertriglyceridemia are anticipated in 2020. We conclude that prescription n-3 FAs (EPA+DHA or EPA-only) at a dose of 4 g/d (>3 g/d total EPA+DHA) are an effective and safe option for reducing triglycerides as monotherapy or as an adjunct to other lipid-lowering agents.
Hypertriglyceridemia (triglycerides 200–499 mg/dL) is relatively common in the United States, whereas more severe triglyceride elevations (very high triglycerides, ≥500 mg/dL) are far less frequently observed. Both are becoming increasingly prevalent in the United States and elsewhere, likely driven in large part by growing rates of obesity and diabetes mellitus.
To read more click on the following link: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000709
This joint position statement from the International Atherosclerosis Society and the International Chair on Cardiometabolic Risk Working Group on Visceral Obesity summarises the evidence for visceral adiposity and ectopic fat as emerging risk factors for type 2 diabetes, atherosclerosis, and cardiovascular disease, with a focus on practical recommendations for health professionals and future directions for research and clinical practice.
For the study, nearly 8,300 people at risk for heart disease had fasting and nonfasting lipid profile tests done at least four weeks apart. (Fasting means they had nothing to eat or drink except water for at least eight hours before the test.) The differences in their total, LDL, and HDL cholesterol values were negligible. Triglyceride levels were modestly higher in the nonfasting samples.
Slower speech, for example, could indicate fatigue or sorrow at one point in time, but over longer periods could signal something more severe, co-founder Jim Harper said.
Dr. Grace Dammann, medical director of the Pain Clinic at Laguna Honda Hospital, and seven of her colleagues talk about what does and does not work in the treatment of chronic pain. She talks as both a patient and a provider. There is also a discussion of various non-pharmacologic and complementary medicine modalities to treat pain.
Antibiotic resistance is a global threat for public health. It is widely acknowledged that antibiotics at sub-inhibitory concentrations are important in disseminating antibiotic resistance via horizontal gene transfer. While there is high use of non-antibiotic human-targeted pharmaceuticals in our societies, the potential contribution of these on the spread of antibiotic resistance has been overlooked so far. Here, we report that commonly consumed non-antibiotic pharmaceuticals, including nonsteroidal anti-inflammatories (ibuprofen, naproxen, diclofenac), a lipid-lowering drug (gemfibrozil), and a β-blocker (propanolol), at clinically and environmentally relevant concentrations, significantly accelerated the conjugation of plasmid-borne antibiotic resistance genes.
The quality scorecard rates health care organizations through a five-star system on more than 30 health measures outlined by an advisory council composed of consumer advocates, providers, community organizations, state agencies, and payers. The range of measures focus on the quality of care provided by primary care providers and span more than 10 areas, including behavioral health, children’s health, women’s health, chronic conditions, and preventative health.
Imagine a smart insulin port attached to your skin, delivering the right dose, and at the right time. At the same moment, getting all information regarding your sugar levels, meds timings and health data, managed and analyzed with the accompanying app.
At the Charité University Hospital in Berlin, I’ve employed what’s called intermittent fasting, or time-restricted eating, to help patients with an array of chronic conditions. These include diabetes, high blood pressure, rheumatism and bowel diseases, as well as pain syndromes such as migraines and osteoarthritis.
Boomers Daily 